Epoch Investment Partners Inc. Acquires 85,742 Shares of Bristol Myers Squibb Company $BMY

Key Points

• Epoch Investment Partners Inc. increased its stake in Bristol Myers Squibb by 8.1% during Q1, now owning approximately 1,144,981 shares valued at $69.8 million.
• As of the latest filings, 76.41% of Bristol Myers Squibb's stock is held by institutional investors, with various funds, including Commonwealth Equity Services LLC and Avaii Wealth Management LLC, enhancing their positions.
• Bristol Myers Squibb reported $1.46 EPS beating analysts' expectations of $1.07, and had a quarterly revenue growth of 0.6% year-over-year.

Epoch Investment Partners Inc. raised its stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 8.1% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,144,981 shares of the biopharmaceutical company's stock after buying an additional 85,742 shares during the quarter. Epoch Investment Partners Inc. owned about 0.06% of Bristol Myers Squibb worth $69,832,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of BMY. Pinney & Scofield Inc. bought a new position in Bristol Myers Squibb in the fourth quarter valued at approximately $25,000. Park Square Financial Group LLC bought a new stake in shares of Bristol Myers Squibb in the fourth quarter worth $26,000. Global Wealth Strategies & Associates lifted its position in shares of Bristol Myers Squibb by 137.5% in the first quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 275 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. bought a new stake in shares of Bristol Myers Squibb in the first quarter worth $31,000. Finally, Accent Capital Management LLC bought a new stake in shares of Bristol Myers Squibb in the first quarter worth $33,000. Institutional investors own 76.41% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently commented on the stock. Daiwa America lowered shares of Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 5th. Daiwa Capital Markets lowered shares of Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 price target on the stock. in a research report on Tuesday, August 5th. Morgan Stanley reaffirmed a "hold" rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. Wall Street Zen lowered shares of Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research report on Friday, June 6th. Finally, Citigroup dropped their price target on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating on the stock in a research report on Friday, August 1st. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $56.38.

Bristol Myers Squibb Stock Performance

Shares of BMY traded up $0.29 during trading hours on Friday, hitting $47.17. The company had a trading volume of 10,685,502 shares, compared to its average volume of 10,735,505. The firm has a market cap of $96.01 billion, a price-to-earnings ratio of 19.02, a PEG ratio of 2.41 and a beta of 0.36. The business has a fifty day moving average of $47.05 and a 200-day moving average of $50.74. Bristol Myers Squibb Company has a 12 month low of $42.96 and a 12 month high of $63.33. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, beating the consensus estimate of $1.07 by $0.39. The company had revenue of $12.27 billion for the quarter, compared to analyst estimates of $11.32 billion. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The company's revenue was up .6% on a year-over-year basis. During the same period in the prior year, the firm earned $2.07 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. Equities analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, August 1st. Investors of record on Thursday, July 3rd were given a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a yield of 5.3%. The ex-dividend date of this dividend was Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 100.00%.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.